GLAXOSMITHKLINE PHARMACEUTICALS
|
The Current P/S Ratio of GLAXOSMITHKLINE PHARMACEUTICALS is 11.13.
| Share Price | ₹2,732.5 | Nov 20,2026 |
| Market Cap | ₹46,288.6 Cr | |
| Sales-TTM | ₹4,158.6 Cr | TTM-Consolidated Results |
| Price/Sales | 11.13x | Calculated as Market Cap/Sales |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PS (Price/Sales) ratio of GLAXOSMITHKLINE PHARMACEUTICALS
P/S =
Market Capitalization
/
Sales
or, using per-share numbers:
P/S = Stock Price / Sales Per Share
Current Market Cap [ ₹46,288.6 Cr] as on Nov 20,2026
(/) Sales [ ₹4,158.6 Cr] based on TTM-Consolidated Results
(=) P/S Ratio [ 11.13x ]
Thus, for GLAXOSMITHKLINE PHARMACEUTICALS , the investors are currently willing to pay '11.13 times sales' to own 1 share of the company.
PS Multiples are one of the most widely used valuation multiple in the industry.
P/S ratios can be a reliable benchmark to compare companies with negative earnings or book value.
You may also explore Price to Earnings ratio or Price to Book ratio of GLAXOSMITHKLINE PHARMACEUTICALS !
The chart below summarizes the trend in P/S Ratio of GLAXOSMITHKLINE PHARMACEUTICALS over the last five years.
Historical PS (Price/Sales) ratio chart of GLAXOSMITHKLINE PHARMACEUTICALS
PS Ratio Performance Analysis for GLAXOSMITHKLINE PHARMACEUTICALS
- GLAXOSMITHKLINE PHARMACEUTICALS 's p/e ratio for fiscal years ending Mar2026 to Mar2022 averaged 9.63x.
- GLAXOSMITHKLINE PHARMACEUTICALS 's operated at median p/e ratio of 9.53x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, GLAXOSMITHKLINE PHARMACEUTICALS 's p/e ratio peaked in Mar2025 at 13x.
- GLAXOSMITHKLINE PHARMACEUTICALS 's p/e ratio hit its five-year low in Mar2023 of 6.9x.
How does GLAXOSMITHKLINE PHARMACEUTICALS 's P/S Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Sales (Cr) | PS Ratio | Market Cap (Cr) |
|---|---|---|---|
| GLAXOSMITHKLINE PHARMACEUTICALS | 4,158.6 | 11.13 | 46,288.6 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 61,630.9 | 7.34 | 452,299.0 |
| DIVIS LABORATORIES LTD | 12,191.0 | 24.39 | 297,325.0 |
| TORRENT PHARMACEUTICALS LTD | 17,400.0 | 10.27 | 178,727.0 |
| CIPLA LTD | 28,138.9 | 4.06 | 114,312.0 |
| DR REDDYS LABORATORIES LTD | 33,097.4 | 3.51 | 116,145.0 |
| MANKIND PHARMA LTD | 15,378.6 | 7.14 | 109,880.0 |
| LUPIN LTD | 30,746.3 | 2.99 | 91,915.9 |
| ZYDUS LIFESCIENCES LTD | 30,378.1 | 3.92 | 119,207.0 |
| AUROBINDO PHARMA LTD | 36,912.9 | 2.80 | 103,298.0 |
| LAURUS LABS LTD | 7,822.5 | 15.85 | 124,002.0 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PS Analysis vs GLAXOSMITHKLINE PHARMACEUTICALS 's P/S Ratio
| Top 10 Industry Peers | PS Ratio |
|---|---|
| Min industry PS | 2.80x |
| Max industry PS | 24.39x |
| Median industry PS | 7.14x |
| Average industry PS | 8.49x |
You may also like the below Video Courses